HUN KIM | President
SK bioscience

HUN KIM, President, SK bioscience

Dr. Hun Kim is the President of Global Business at SK bioscience. His role is to oversee the company’s product and platform portfolio in a comprehensive perspective from R&D to commercialization through global alliance and external innovation. Dr. Hun Kim started his biopharmaceutical career in 1992 as a researcher at Green Cross Corporation. In 2000, he moved on to Berna Biotech, a part of Crucell at present. In 2008, He joined SK Chemicals, the parent company of SK bioscience, and lead the company’s expansion in vaccine R&D capabilities.  Under his oversight as the President of Global R&BD, the company successfully developed and received approval for cell culture-based influenza vaccines (SKYCellflu / SKYCellflu Quadrivalent) and varicella/herpes zoster vaccines (SKYVaricella / SKYZoster).


Day 2 - Wednesday 3rd April @ 09:00

Panel: Vaccine manufacturing insights from Asia: Strengthening vaccine production capacity and capabilities

  • Lessons from the rapid scale up of production capacity to meet pandemic vaccine demand and how we maintain these capabilities post-pandemic.
  • How do we stimulate global collaboration between Asia and the rest of the world?
  • Strengthening of regulatory systems and alignment between countries
  • What is Asia’s appetite in introducing new technologies into their manufacturing capabilities?
last published: 26/Feb/24 13:16 GMT

back to speakers